α-PD-1 or α-CD137 mAbs alone did not significantly enhance the anti-tumor effect of SBRT (mean TDT: SBRT + α-PD-1: 32.3 days, SBRT + α-CD137: 43.1 days vs. SBRT: 40.8 days). The gene discussed is TNFRSF9; the disease is neoplasm.